SuperworthNeuphoria Therapeutics EPS NEUP
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$6.18
- Latest quarter, Q4 FY26
- −$0.91
- Fiscal year 2026
- −$6.18
Neuphoria Therapeutics' earnings per share was −$6.18 over the twelve months to Jun 30, 2026.
In its latest quarter, Q4 FY26, it was −$0.91.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$6.18 | n/a |
| FY2025 | −$0.53 | n/a |
| FY2024 | −$9.38 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | −$0.91 | n/a | −$6.18 | |
| Q3 FY26 | −$0.09 | −101% | −$9.94 | |
| Q2 FY26 | −$0.77 | n/a | −$3.30 | |
| Q1 FY26 | −$4.41 | n/a | −$4.32 | |
| Q4 FY25 | −$4.67 | n/a | −$0.53 | |
| Q3 FY25 | $6.55 | n/a | $2.90 | |
| Q2 FY25 | −$1.79 | n/a | −$6.48 | |
| Q1 FY25 | −$0.62 | n/a | −$10.00 | |
| Q4 FY24 | −$1.24 | n/a | −$9.38 | |
| Q3 FY24 | −$2.83 | n/a | n/a | |
| Q2 FY24 | −$5.31 | n/a | n/a | |
| Q1 FY24 | $0.00 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Neuphoria Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NEUPNeuphoria Therapeutics | −$6.18 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Neuphoria Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.